NCT00799942

Open-lable Extension Study on Safety and Efficacy of Neramexane to Treat Congenital and Acquired Nystagmus

Long-term Open-label Extension Study to Assess the Safety, Tolerability, and Efficacy of Neramexane Mesylate in Congenital Idiopathic Nystagmus and Acquired Nystagmus

• Status: Terminated
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 48 (estimated)
• Sponsor: Merz Pharmaceuticals GmbH · Industry
• Sex: All
• Age: 18 Years – 81 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to investigate the long-term safety, tolerability and efficacy of neramexane mesylate in the treatment of congenital idiopathic nystagmus (CIN). In addition, a subgroup of multiple sclerosis (MS) patients suffering from acquired nystagmus will be included.

Conditions

• Nystagmus, Congenital
• Nystagmus, Acquired
• Multiple Sclerosis

Interventions

Type	Name	Description
DRUG	Neramexane mesylate	open-label treatment of 36 months Neramexane mesylate up to 75 mg per day

Timeline

• Start date: 2009-05-01
• First posted: 2008-12-01
• Last updated: 2010-07-01

Locations

1 site across 1 country: United Kingdom